SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal antibodies using its proprietary Transchromosomic (Tc) Bovine platform. The company went public through a SPAC merger with Big Rock Partners Acquisition Corp, sponsored by Big Rock Partners LLC, which completed its IPO in 2020; the business combination closed in October 2021. As of its DEF 14A proxy statement filed April 30, 2026, SABS remains a publicly traded entity on Nasdaq, continuing to advance its pipeline of immunology and infectious disease therapeutics. For comprehensive filing history, sponsor details, and deal metrics on SABS and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.